Cardiopulmonary changes and its association with clinical features in noncirrhotic portal hypertension
Harish Gopalakrishna(National Institutes of Health), Theo Heller(National Institutes of Health), Vandana Sachdev(National Heart Lung and Blood Institute), David E. Kleiner, Rownock Afruza(National Institute of Diabetes and Digestive and Kidney Diseases), Maria Mironova(National Institutes of Health), Michael B. Fallon(University of Arizona), Christopher Koh(National Institutes of Health), Gayatri B Nair(Georgetown University), Matthew G Menkart(National Institute of Diabetes and Digestive and Kidney Diseases), Jenna L Oringher(National Institute of Diabetes and Digestive and Kidney Diseases), Gracia M. Viana Rodriguez(National Institutes of Health), Moumita Chakraborty(National Institute of Diabetes and Digestive and Kidney Diseases), Shani Scott(National Institutes of Health), My‐Le Nguyen(National Institutes of Health)
Cited by 0
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k